MD Anderson CPRIT TRIUMPH Postdoc Fellowship – PhDs, Houston, Texas, USA
MD Anderson Cancer Center offers the CPRIT TRIUMPH Fellowship, a postdoctoral fellowship in Houston, Texas, for Ph.D. graduates to pursue translational cancer research. Apply by 31 December 2026.
Job Details
Title: CPRIT TRIUMPH Postdoctoral Fellowship
Organization: MD Anderson Cancer Center
Location: Houston, Texas, USA
MD Anderson Postdoctoral Fellowship Eligibility Criteria
- Must have (or be near completion of) a Ph.D. degree from a top graduate program (U.S. or abroad) in any of the life or natural sciences within the last three years.
- Dedication to pursue translational cancer research.
- Publications in top tier journals (recent graduates must have at least one accepted or published first or co-first author paper in a journal with an impact factor around 8 at the time of application).
- All foreign fellows must have an active visa for the duration of the fellowship.
How to Apply
For the CPRIT TRIUMPH Fellowship, please email all documents to Dr. Monica Galaz Montoya ([email protected]) for submission. Applications should include:
- Curriculum Vitae
- PDF reprints of all first author publications
- Three letters of recommendation – should be written on official letter head and contain original signatures, submitted by email from the referees’ institutional/organizational email account to Dr. Monica Galaz Montoya ([email protected]).
- A two-page essay describing your goals and dedication toward a career in translational cancer research (single-spaced and in 12-point Arial or Times New Roman font).
- A recorded 90-second elevator speech (sent as a MOV file or mp4) that highlights your most significant research.
Important Dates
The current application cycle closes on 31 December 2026. There will be four annual application cycle deadlines for 2026: March 31, 2026; June 30, 2026; September 30, 2026; and December 31, 2026.
CLICK HERE FOR THE ORIGINAL NOTIFICATION / APPLY ONLINE
Submit your CPRIT TRIUMPH Fellowship application by the deadline of 31 December 2026.
Questions and comments